📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-21 14:59
232 analysed today
FollowTelegram
232
Today
149,633
All-time analysed
42,906
Positive
6,661
Negative
91,389
Neutral
8,609
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
18 announcements match the current filters (relevance ≥ 5).
Q1-FY27 Presentation: EBITDA Jumps 67.7% YoY to ₹416 Cr with Margin at 17.97%
Valiant Organics released its Q1-FY27 earnings presentation, highlighting strong operational recovery with revenue growing 13.3% YoY to ₹231.5 Cr (INR 2,315 Mn). Operating EBITDA surged 67.7% YoY to ₹41.6 Cr as EBITDA margin expanded by 584 bps to 17.97%, driven by a 410 bps drop in raw material costs as a percentage of sales. Consolidated PAT rose sharply to ₹29.3 Cr from ₹8.2 Cr in Q1-FY26, supported by higher operating leverage and an increased share of profit from associates.
Confidence: HIGH
What changedThe company issued its Q1-FY27 investor presentation detailing quarterly chemistry-wise operational performance and margin expansion.
Why it mattersDemonstrates clear profitability recovery from the H1-FY26 trough, driven by lower input costs and better operating leverage across its hydrogenation and chlorination segments.
Q1 Operational Revenue: INR 2,315 MnQ1 Operating EBITDA: INR 416 MnEBITDA Margin: 17.97%Q1 Consolidated PAT: INR 293 MnTotal Production Capacity: 70,000 TPA
📅 Short termPositive sentiment likely given the notable margin expansion to 17.97% and quarterly PAT rebound.
📈 Long termThe company's position as a leading domestic manufacturer of chlorophenol derivatives and benzene-based intermediates offers operating leverage as end-user demand normalizes.
⚠ Risk flags
- End-user industry demand cyclicality in Dyes, Pigments, and Agrochemicals
- Volatility in raw material prices impacting gross margin sustainability
Key Highlights
Revenue from operations grew 13.3% YoY to INR 2,315 Mn (highest in the last six quarters)
Operating EBITDA rose 67.7% YoY to INR 416 Mn with EBITDA margin expanding 584 bps to 17.97%
Raw material costs declined from 61% to 57% of sales, expanding gross margins to 43%
Consolidated PAT surged to INR 293 Mn (EPS INR 10.44 vs INR 2.93 in Q1-FY26)
Total manufacturing capacity stands at 70,000 TPA across 6 units in 5 locations
👀 What to Watch
Track the sustainability of operating margins above 15% in subsequent quarters and volume recovery in key user industries like dyes, pigments, and agrochemicals.
Valiant Organics Q1 PAT Jumps 188% YoY to ₹21.82 Cr; MD Re-appointed for 3 Years
Valiant Organics reported a strong start to FY27 with standalone revenue growing 13.3% YoY to ₹231.54 Cr. Net profit surged 188% YoY to ₹21.82 Cr, significantly exceeding the quarterly average of the previous year. A key driver was the Pharma division, which turned around from a loss of ₹0.21 Cr to a profit of ₹16.85 Cr at the segment level. The board also ensured leadership continuity by re-appointing MD Sathiababu K. Kallada for a three-year term starting May 2027.
Confidence: HIGH
What changedThe company has reported a significant recovery in profitability and segment performance for Q1 FY27, alongside securing leadership for the next three years.
Why it mattersThe sharp jump in PAT and the turnaround in the Pharma segment suggest improved cost absorption and potentially better product pricing, addressing previous concerns about tepid demand in end-user industries.
Standalone Revenue (Q1 FY27): ₹231.54 CrStandalone PAT (Q1 FY27): ₹21.82 CrPharma Segment Result (Q1 FY27): ₹16.85 CrQ1 Revenue vs TTM Revenue: 31.3%MD Re-appointment Term: 3 Years
📅 Short termThe stock is likely to react positively in the short term due to the substantial earnings beat and the turnaround in the Pharma segment.
📈 Long termIf the company maintains this margin profile (EBITDA recovery noted in context), it could lead to a re-rating, especially if the Pharma division continues to contribute meaningfully to the bottom line.
⚠ Risk flags
- High debt of ₹219 Cr relative to annual PAT
- Sensitivity to demand in Pharma and Agro-chemical sectors
- Office relocation involves changing ROC jurisdictions
Key Highlights
Standalone Revenue from Operations rose 13.3% YoY to ₹231.54 Cr in Q1 FY27.
Standalone Net Profit increased by 188% to ₹21.82 Cr from ₹7.58 Cr in the year-ago quarter.
Pharma Division segment results improved to a profit of ₹16.85 Cr from a loss of ₹0.21 Cr YoY.
Specialty Chemical Division revenue grew 16.6% YoY to ₹175.74 Cr.
MD Sathiababu K. Kallada re-appointed for a 3-year term effective May 24, 2027.
👀 What to Watch
Investors should monitor if the Pharma segment's sudden profitability is sustainable or driven by one-off orders. Watch for the upcoming AGM for shareholder approval of the MD's re-appointment and the registered office relocation to Tarapur.
₹29.26 Cr Q1 PAT: Valiant Organics Reports 257% YoY Profit Growth; MD Re-appointed
Valiant Organics reported a strong performance for Q1 FY27, with consolidated revenue reaching ₹231.54 crore, a 13.3% increase from ₹204.41 crore in the same quarter last year. Consolidated net profit surged by 257% YoY to ₹29.26 crore, driven by a significant turnaround in the Pharma division which posted segment results of ₹16.85 crore compared to a loss of ₹0.21 crore YoY. The board also approved the re-appointment of Managing Director Sathiababu K. Kallada for a three-year term starting May 2027 and the relocation of the registered office to Tarapur, Palghar.
Confidence: HIGH
What changedThe company has demonstrated a significant recovery in profitability and confirmed leadership continuity for the next three years while consolidating administrative operations.
Why it mattersThe 257% YoY profit growth indicates a strong recovery from previous tepid demand cycles in the chemical and pharma sectors, significantly improving the company's earnings profile relative to its ₹868 Cr market cap.
Consolidated Revenue (Q1 FY27): ₹231.54 CrConsolidated Net Profit (Q1 FY27): ₹29.26 CrYoY Revenue Growth: 13.3%Pharma Segment Result: ₹16.85 CrMD Re-appointment Term: 3 Years
📅 Short termThe stock is likely to react positively to the substantial earnings beat and the turnaround in the Pharma division's profitability.
📈 Long termLeadership stability and the recovery of margins toward the 12% threshold are structural positives for long-term valuation re-rating.
⚠ Risk flags
- Shareholder approval pending for MD re-appointment
- Volatility in raw material spreads
- Dependence on demand from the cyclical Agro-chemical sector
Key Highlights
Consolidated Net Profit for Q1 FY27 jumped to ₹29.26 crore from ₹8.20 crore in Q1 FY26.
Pharma division segment results turned positive at ₹16.85 crore vs a loss of ₹0.21 crore in the previous year's quarter.
Specialty Chemical division revenue grew to ₹175.74 crore, representing 76% of total quarterly revenue.
Managing Director Sathiababu K. Kallada re-appointed for a 3-year term effective May 24, 2027.
Company shifting registered office to MIDC Tarapur and corporate office to Vikhroli, Mumbai.
👀 What to Watch
Investors should monitor if the sharp margin recovery in the Pharma segment is sustainable over the coming quarters and watch for shareholder approval of the MD's re-appointment at the upcoming AGM.
Valiant Organics Q1 PAT jumps 257% YoY to ₹29.26 Cr; MD re-appointed for 3 years
Valiant Organics reported a strong start to FY27 with consolidated revenue growing 13.3% YoY to ₹231.54 Cr. Net profit surged to ₹29.26 Cr from ₹8.20 Cr in the year-ago period, primarily driven by a sharp turnaround in the Pharma division which posted a segment profit of ₹16.85 Cr against a loss previously. The board also approved the re-appointment of Managing Director Sathiababu K. Kallada for a three-year term starting May 2027, ensuring leadership continuity. Additionally, the company is relocating its registered office to Tarapur, Maharashtra, to align with its manufacturing presence.
Confidence: HIGH
What changedThe company reported a significant recovery in quarterly profitability and confirmed the extension of its Managing Director's tenure until 2030.
Why it mattersThe turnaround in the Pharma segment is critical as it was previously a drag on margins; sustained performance here could lead to a re-rating of the stock given the current P/E of 25.3.
Consolidated Revenue (Q1 FY27): ₹231.54 CrConsolidated PAT (Q1 FY27): ₹29.26 CrPharma Segment Result: ₹16.85 CrYoY PAT Growth: 256.8%MD Tenure Extension: 3 years
📅 Short termThe stock is likely to react positively in the short term due to the substantial earnings beat and the sharp recovery in segment margins.
📈 Long termLeadership continuity and the shift towards a more profitable Pharma mix are structural positives, though the company must manage its ₹219 Cr debt load.
⚠ Risk flags
- Sustainability of Pharma segment margins
- High debt-to-equity relative to small-cap size
- Sensitivity to raw material price volatility in specialty chemicals
Key Highlights
Consolidated Net Profit increased by 256.8% YoY to ₹29.26 Cr in Q1 FY27
Pharma division segment results turned positive at ₹16.85 Cr compared to a loss of ₹0.21 Cr in Q1 FY26
Consolidated Revenue from operations grew 13.3% YoY to ₹231.54 Cr
Basic EPS improved significantly to ₹10.44 from ₹2.93 in the corresponding quarter last year
MD Sathiababu K. Kallada re-appointed for a 3-year term effective from May 24, 2027
👀 What to Watch
Investors should monitor if the Pharma division's sudden profitability is sustainable or driven by one-off orders, and track the impact of the office relocation on administrative costs.
Valiant Organics Q1 PAT Jumps 257% YoY to ₹29.26 Cr; Pharma Segment Turns Profitable
Valiant Organics reported a robust Q1 FY27 with consolidated revenue growing 13.3% YoY to ₹231.54 Cr. The standout feature was the net profit, which surged 256.8% YoY to ₹29.26 Cr, nearly matching the entire TTM PAT of ₹34 Cr in a single quarter. This performance was driven by a significant turnaround in the Pharma division, which posted an EBIT of ₹16.85 Cr against a loss of ₹0.21 Cr in the previous year. The Specialty Chemicals division also maintained momentum with a 44% YoY increase in EBIT to ₹25.06 Cr.
Confidence: HIGH
What changedThe company has achieved a major operational turnaround in its Pharma division and a significant expansion in overall margins compared to the previous fiscal year.
Why it mattersThe Q1 profit of ₹29.26 Cr is approximately 86% of the total TTM PAT, indicating a potential for a massive earnings upgrade for FY27 if this run rate continues.
Consolidated Revenue (Q1): ₹231.54 CrConsolidated PAT (Q1): ₹29.26 CrPharma Segment EBIT: ₹16.85 CrQ1 PAT vs TTM PAT: 86.05%YoY Revenue Growth: 13.3%
📅 Short termThe stock is likely to react positively to the substantial earnings beat and the turnaround in the Pharma segment.
📈 Long termIf the company maintains these improved margins across both segments, it could lead to a significant re-rating of the stock, which has been under pressure over the last 12 months.
⚠ Risk flags
- Sustainability of Pharma segment margins
- High finance costs (₹5.13 Cr in Q1 vs ₹18.20 Cr TTM)
- Concentration in specialty chemical intermediates
Key Highlights
Consolidated Net Profit surged to ₹29.26 Cr in Q1 FY27 from ₹8.20 Cr in Q1 FY26.
Pharma division EBIT turned around to ₹16.85 Cr from a loss of ₹0.21 Cr YoY.
Consolidated Revenue from operations increased 13.3% YoY to ₹231.54 Cr.
Specialty Chemicals segment EBIT grew 44.3% YoY to ₹25.06 Cr.
Managing Director Sathiababu K. Kallada re-appointed for a 3-year term starting May 2027.
👀 What to Watch
Investors should monitor if the Pharma segment's sudden profitability is sustainable or driven by one-off orders. The sharp improvement in margins (PBT margin at 15.9% vs 5.4% YoY) warrants a close look at the next quarter's performance to confirm a structural turnaround.
Valiant Organics: CRISIL Revises Outlook to 'Stable' from 'Negative'; Reaffirms 'A-' Rating
CRISIL has revised the outlook on Valiant Organics' Rs 370 crore bank facilities to 'Stable' from 'Negative', while reaffirming the 'CRISIL A-' rating. This revision follows a significant operational turnaround in FY26, where the company reported a PAT of Rs 33.23 crore compared to a loss of Rs 3.43 crore in FY25. Operating margins improved to 12.75% in FY26 from 7.38% in FY25, driven by capacity ramp-up and steady demand. The financial risk profile remains healthy with a low gearing of 0.34x and improved interest coverage of 5.23x.
Confidence: HIGH
What changedCRISIL revised the credit outlook from 'Negative' to 'Stable', reflecting improved business risk and profitability.
Why it mattersThe outlook revision validates the company's operational recovery and reduces the risk of a credit downgrade, which can lead to better borrowing terms and improved investor confidence.
Total Bank Facilities Rated: Rs 370 CroreFY26 Operating Margin: 12.75%FY26 PAT: Rs 33.23 CroreGearing Ratio (Mar 2026): 0.34 timeInterest Coverage: 5.23 timesGross Current Assets (GCA): 177 days
📅 Short termThe outlook upgrade is likely to be viewed positively by the market in the coming days as it confirms the company's exit from a period of constrained profitability.
📈 Long termThe company's focus on diverse product portfolios in Pharma and Agro-chemicals, combined with logistical advantages, supports a steady 8-10% revenue growth target over the medium term.
⚠ Risk flags
- Large working capital requirement (177 days GCA)
- Vulnerability to raw material price volatility
- High import dependence
Key Highlights
Outlook revised to 'Stable' from 'Negative' for Rs 370 crore bank loan facilities
Operating margin recovered to 12.75% in FY26 from 7.38% in FY25
Interest coverage ratio improved significantly to 5.23x in FY26 from 2.30x in FY25
Net worth increased to Rs 746 crore as of March 31, 2026, against Rs 712 crore in the previous year
Net cash accruals expected at Rs 70-80 crore per annum against yearly debt obligations of Rs 17-18 crore
👀 What to Watch
Monitor the company's ability to sustain operating margins above the 13% threshold, which CRISIL identifies as a trigger for a potential rating upgrade. Additionally, watch for any reduction in the working capital cycle, which remains high at 177 days.
Valiant Organics Cancels Postal Ballot for Cessation of Partnership in Dhanvallabh Ventures LLP
Valiant Organics Limited has decided to halt its withdrawal as a partner from Dhanvallabh Ventures LLP. Following a board meeting on June 18, 2026, the company also cancelled a material related party transaction associated with this move. Consequently, the ongoing postal ballot process and the electronic voting event (EVEN - 139390) have been withdrawn with immediate effect. The board plans to deliberate further on the matter before making a final decision.
Key Highlights
Board decided not to proceed with cessation as a partner of Dhanvallabh Ventures LLP for the time being.
Related material related party transaction (RPT) has been put on hold following Audit Committee recommendations.
Postal ballot process and electronic voting (EVEN - 139390) stand cancelled with immediate effect.
The decision was based on management evaluation and submissions made during the June 18, 2026, board meeting.
👀 What to Watch
Investors should monitor future announcements for the rationale behind halting this transaction and its impact on the company's corporate structure. No immediate action is required as the status quo remains for the partnership.
Valiant Organics Cancels Postal Ballot for Dhanvallabh Ventures LLP Exit and Related Party Deal
Valiant Organics Limited has decided not to proceed with its planned cessation as a partner in Dhanvallabh Ventures LLP. This decision also halts the associated material related party transaction for the time being, following recommendations from the Audit Committee. Consequently, the company has cancelled the ongoing postal ballot process and withdrawn the electronic voting event (EVEN - 139390) with immediate effect. The board intends to further deliberate on the matter before taking any future steps.
Key Highlights
Board decided to halt the transaction involving cessation as a partner of Dhanvallabh Ventures LLP.
Material related party transaction associated with the exit is deferred for the time being.
Ongoing postal ballot process and electronic voting (EVEN - 139390) stand cancelled immediately.
Decision was based on the evaluation by the Audit Committee and management submissions.
Board meeting concluded at 5:05 P.M. IST on June 18, 2026.
👀 What to Watch
Investors should exercise caution and wait for further clarity on why the material related party transaction was abruptly cancelled. Monitor future disclosures for updates on the company's strategy regarding its partnership in Dhanvallabh Ventures LLP.
Valiant Organics FY26 PAT Surges to ₹332 Mn; EBITDA Margins Expand to 11.94%
Valiant Organics reported a significant turnaround in FY26, with consolidated revenue growing 2.8% YoY to ₹7,388 million. The company achieved a Profit After Tax (PAT) of ₹332 million, recovering from a loss of ₹34 million in the previous fiscal year. EBITDA saw robust growth of 64.2% YoY to ₹882 million, driven by structural cost optimization and improved operational execution. The company's EBITDA margins expanded significantly by 447 basis points to reach 11.94% for the full year, supported by a strong Q4 performance.
Key Highlights
FY26 Revenue increased to ₹7,388 Mn with a 64.2% YoY surge in EBITDA to ₹882 Mn.
EBITDA margins expanded by 447 bps YoY to 11.94% due to raw material optimization and tighter overhead control.
The company turned profitable with a PAT of ₹332 Mn in FY26 compared to a loss of ₹34 Mn in FY25.
Hydrogenation remains the largest chemistry segment, contributing 48% of FY26 revenue.
Q4 FY26 performance was strong with revenue of ₹2,178 Mn and an improved PAT margin of 7.21%.
👀 What to Watch
Investors should note the strong operational turnaround and margin recovery, which suggests improved efficiency and successful cost management. The stock may see positive momentum if the company sustains this profitability trend in the specialty chemicals sector.
Valiant Organics to Exit Dhanvallabh Ventures LLP; To Acquire 34.26% Stake in Valiant Laboratories
Valiant Organics Limited is seeking shareholder approval to cease its 73.15% partnership interest in its material subsidiary, Dhanvallabh Ventures LLP (DVLLP). As part of the settlement, the company will receive 1,86,07,531 equity shares of Valiant Laboratories Limited (VLL), which represents approximately 34.26% of VLL's equity capital. Additionally, Valiant Organics will pay Rs. 6.34 crore to DVLLP to adjust its proportionate capital contribution. This restructuring effectively converts an indirect holding into a direct equity stake in Valiant Laboratories.
Key Highlights
Cessation of 73.15% partnership interest in material subsidiary Dhanvallabh Ventures LLP
Acquisition of 1,86,07,531 equity shares of Valiant Laboratories Limited (34.26% stake)
Payment of Rs. 6,34,34,544 by Valiant Organics to DVLLP for capital adjustment
Transaction to be settled via inter-se off-market transfer based on fair market value
E-voting period for shareholders concludes on June 21, 2026
👀 What to Watch
Investors should monitor the valuation of Valiant Laboratories Limited shares relative to the cash outflow to ensure the swap is value-accretive. The move simplifies the corporate structure by moving from an LLP partnership to direct equity ownership.
Valiant Organics to Receive 1.86 Cr Valiant Lab Shares in LLP Exit Settlement
Valiant Organics Limited has issued a corrigendum regarding its exit as a partner from Dhanvallabh Ventures LLP (DVLLP). As part of the settlement for its capital and profits, the company will receive 1,86,07,531 equity shares of Valiant Laboratories Limited. Simultaneously, Valiant Organics will pay Rs. 6.34 crore to DVLLP to adjust its proportionate capital contribution. This material related party transaction is expected to conclude within 60 days of obtaining shareholder approval.
Key Highlights
Cessation of partnership in Dhanvallabh Ventures LLP (DVLLP) approved by the Board.
Settlement includes the transfer of 1,86,07,531 equity shares of Valiant Laboratories Limited to the company.
Valiant Organics to pay Rs. 6,34,34,544 (inclusive of taxes) to DVLLP for capital adjustments.
Transaction is based on fair market value and conducted on an arm's length basis.
Expected completion within 60 days of receiving necessary shareholder and regulatory approvals.
👀 What to Watch
Investors should monitor the market value of Valiant Laboratories Limited shares as they will now be a direct asset for Valiant Organics. Assess the impact of the Rs. 6.34 crore cash outflow against the liquidity and value of the shares received.
Valiant Organics to Exit Subsidiary DVLLP; to Receive 1.86 Cr Shares of Valiant Laboratories
Valiant Organics' board has approved the cessation of the company as a partner in Dhanvallabh Ventures LLP (DVLLP), which will consequently cease to be a subsidiary. To settle the company's capital and profit share, DVLLP will transfer 1,86,07,531 equity shares of Valiant Laboratories Limited to Valiant Organics. While DVLLP contributed 11.34% (₹83.79 Crores) to the consolidated net worth in FY26, its revenue contribution was negligible at 0.05% (₹0.37 Crores). The transaction is a material related party transaction and requires shareholder approval via a special resolution.
Key Highlights
Valiant Organics to exit Dhanvallabh Ventures LLP (DVLLP), ending its status as a subsidiary.
Settlement involves receiving 1,86,07,531 equity shares of Valiant Laboratories Limited from DVLLP.
DVLLP contributed ₹83.79 Crores (11.34%) to consolidated net worth but only ₹0.37 Crores (0.05%) to revenue in FY26.
The transaction is based on a valuation report by GBCA & Associates LLP and is conducted at arm's length.
Completion is expected within 60 days of receiving shareholder approval.
👀 What to Watch
Investors should monitor the market value of Valiant Laboratories shares as they will now be held directly on the balance sheet. This restructuring simplifies the corporate structure without impacting core operating revenue.
Valiant Organics Board Approves Evaluation of Corporate Restructuring Options
Valiant Organics' Board has granted in-principle approval to explore various restructuring options, including potential mergers, demergers, or reorganizations involving its subsidiaries and associates. The primary goal is to simplify the complex holding structure and achieve operational and strategic synergies across its business units. This move is intended to unlock long-term value for shareholders and create more focused business platforms. While the evaluation process has begun, the company has not yet committed to a specific transaction or timeline.
Key Highlights
Board granted in-principle approval on May 16, 2026, to evaluate restructuring options including mergers and demergers.
The initiative aims to simplify the existing holding structure and achieve organizational synergies across its 6 manufacturing units.
Potential outcomes include unlocking long-term shareholder value and creating strategically aligned business platforms.
The Board will be apprised of the evaluation outcomes before determining the final course of action.
👀 What to Watch
Investors should monitor for specific details on the restructuring plan, as a demerger of specific business lines could provide a valuation re-rating. No immediate action is required until the definitive terms and ratios are announced.
Valiant Organics Q4 Net Profit Jumps 282% to ₹15.1 Cr; FY26 Turnaround to ₹34.4 Cr Profit
Valiant Organics reported a significant turnaround in FY26, posting a standalone net profit of ₹34.36 crore compared to a loss of ₹3.0 crore in FY25. Revenue for the full year grew marginally to ₹738.38 crore, while Q4 FY26 revenue rose 6.8% YoY to ₹217.70 crore. The bottom line was bolstered by a sharp 282% YoY increase in Q4 profit and a reduction in annual finance costs from ₹24.05 crore to ₹18.20 crore. Strategically, the company has also identified 'Pharma Business' as a new reportable segment, signaling a diversification beyond specialty chemicals.
Key Highlights
Standalone Net Profit for FY26 reached ₹34.36 Cr, a sharp recovery from a loss of ₹3.0 Cr in FY25.
Q4 FY26 Revenue from Operations increased to ₹217.70 Cr, up 6.8% from ₹203.81 Cr in the same quarter last year.
Finance costs for the full year were reduced by 24.3%, falling to ₹18.20 Cr from ₹24.05 Cr.
The Board approved the identification of 'Pharma Business' as a new reportable segment alongside Specialty Chemicals.
Exceptional gain of ₹5.72 Cr recorded during the year contributed to the overall profitability improvement.
👀 What to Watch
The company's return to profitability and successful debt/finance cost management are strong positive indicators. Investors should watch for the growth trajectory and margin profile of the newly classified Pharma segment in upcoming quarters.
Valiant Organics Q4 FY26 Net Profit Surges 282% YoY to ₹15.12 Cr; Full Year Turnaround Reported
Valiant Organics reported a strong performance for Q4 FY26, with standalone revenue growing 6.8% YoY to ₹217.7 crore and net profit jumping significantly to ₹15.12 crore. The company achieved a full-year turnaround, posting a net profit of ₹34.36 crore in FY26 compared to a loss of ₹3 crore in FY25. A key strategic development is the formal identification of the Pharma Business as a separate reportable segment, indicating a diversification focus. Additionally, finance costs saw a notable reduction of 24% for the full year, improving the bottom line.
Key Highlights
Standalone Net Profit for Q4 FY26 rose 282% YoY to ₹15.12 crore from ₹3.96 crore in the previous year.
Full-year FY26 revenue stood at ₹738.38 crore, showing steady growth from ₹718.76 crore in FY25.
Achieved a significant full-year profit turnaround with ₹34.36 crore net profit versus a loss of ₹3 crore in FY25.
Finance costs for FY26 reduced to ₹18.20 crore from ₹24.05 crore, reflecting improved debt management.
Management formally identified the 'Pharma Business' as a new reportable segment alongside Specialty Chemicals.
👀 What to Watch
The company shows strong recovery signs with a significant profit turnaround and reduced interest burden. Investors should monitor the growth and margins of the newly identified Pharma segment as a potential long-term value driver.
Valiant Organics Q3 FY26: 9M EBITDA Jumps 84% YoY to ₹616 Mn; PAT Turns Positive
Valiant Organics reported a strong turnaround for the 9-month period ending December 2025, with PAT reaching ₹175 Mn compared to a loss of ₹76 Mn in the previous year. While Q3 revenue faced a 14.8% YoY decline to ₹1,593 Mn due to pricing pressures and demand softness, the company's 9M EBITDA margin expanded significantly by 533 bps to 11.82%. Gross profit margins improved to 43%, reflecting better cost efficiencies and pricing discipline. The results were also supported by an exceptional insurance claim of ₹57 Mn.
Key Highlights
9M-FY26 EBITDA surged 84.4% YoY to ₹616 Mn with margins expanding to 11.82%
Turnaround in profitability with 9M PAT at ₹175 Mn vs a loss of ₹76 Mn in 9M-FY25
Gross profit margin expanded by over 500 bps to 43% in 9M-FY26
Q3-FY26 revenue declined 14.8% YoY to ₹1,593 Mn due to pricing and demand headwinds
Exceptional income of ₹57 Mn from an insurance claim boosted the bottom line
👀 What to Watch
Investors should focus on the significant margin recovery and the company's ability to turn profitable despite industry-wide pricing pressures. Monitor the stabilization of the Chlorination and Hydrogenation segments for sustained growth.
Valiant Organics Q3 FY26 Net Profit Rises 30.5% YoY to ₹6.06 Cr; Exceptional Gain of ₹5.72 Cr
Valiant Organics reported a standalone net profit of ₹6.06 crore for the quarter ended December 31, 2025, marking a 30.5% increase from ₹4.65 crore in the previous year's corresponding quarter. While revenue from operations declined 14.8% year-on-year to ₹159.07 crore, the company showed sequential stability. Profitability was significantly aided by an exceptional gain of ₹5.72 crore from a fire insurance claim settlement. Notably, the company has achieved a turnaround for the nine-month period, posting a profit of ₹19.24 crore compared to a loss of ₹6.95 crore in the prior year period.
Key Highlights
Standalone Net Profit increased to ₹6.06 crore in Q3 FY26 from ₹4.65 crore in Q3 FY25.
Revenue from operations stood at ₹159.07 crore, a slight sequential increase from ₹157.21 crore in Q2 FY26.
Recognized an exceptional gain of ₹5.72 crore relating to a fire insurance claim settlement for the Sarigam Division.
Finance costs decreased significantly to ₹4.56 crore compared to ₹5.83 crore in the same quarter last year.
9-month FY26 standalone profit reached ₹19.24 crore, reversing a net loss of ₹6.95 crore in 9M FY25.
👀 What to Watch
Investors should note the company's successful turnaround into profitability and the reduction in finance costs, which indicates better debt management. Monitor the execution of the new manufacturing agreement with Aarti Pharmalabs for potential long-term revenue growth.
Valiant Organics Q3 Standalone Net Profit Rises 30.5% YoY to ₹6.06 Cr; Revenue Dips 14.8%
Valiant Organics reported a standalone net profit of ₹6.06 crore for Q3 FY26, a 30.5% increase from ₹4.65 crore in the same quarter last year, despite a 14.8% decline in revenue to ₹159.07 crore. The bottom line was significantly bolstered by an exceptional gain of ₹5.72 crore from a fire insurance claim settlement related to a past fire incident. For the nine-month period ended December 2025, the company achieved a major turnaround with a profit of ₹19.24 crore compared to a loss of ₹6.95 crore in the previous year. Finance costs also saw a healthy reduction, dropping to ₹4.56 crore from ₹5.83 crore YoY.
Key Highlights
Standalone Net Profit grew 30.5% YoY to ₹6.06 crore, aided by a ₹5.72 crore exceptional insurance gain.
Revenue from operations fell 14.8% YoY to ₹159.07 crore, though it showed a marginal 1.2% growth on a QoQ basis.
9M FY26 performance shows a sharp recovery with a net profit of ₹19.24 crore versus a loss of ₹6.95 crore in 9M FY25.
Finance costs for the quarter reduced by 21.8% YoY to ₹4.56 crore, reflecting improved debt management.
Basic EPS improved significantly to ₹2.16 in Q3 FY26 from ₹1.18 in the corresponding quarter of the previous year.
👀 What to Watch
The company has successfully turned around from last year's losses, though the YoY revenue decline suggests ongoing pricing or volume pressure in the chemicals sector. Investors should monitor if core operational profitability can be sustained in the absence of one-time insurance gains.
